From the Journals

Siponimod trial ‘first’ to show delayed disability in secondary progressive MS


 

FROM THE LANCET

The EXPAND study was funded by Novartis. The lead author Dr. Kappos has received research and educational support funding via his institution from Novartis and multiple other pharmaceutical companies. Editorial author Dr. Metz has received grants from Roche and Biogen and personal fees from EMD Serono. The other editorial author, Dr. Liu, reported receiving personal fees from Novartis and personal fees and grants from EMD Serono. Dr. Liu was a back-up treating neurologist in the EXPAND trial.

SOURCE: Kappos L et al. Lancet. 2018 Mar 22. doi: 10.1016/S0140-6736(18)30475-6, and Metz L and Liu W. Lancet. 2018 Mar 22. doi: 10.1016/S0140-6736(18)30426-4.

Pages

Recommended Reading

Does Vitamin D Level Affect Progressive MS?
MDedge Neurology
Health Care Use May Elucidate MS Prodrome
MDedge Neurology
How Are Newer DMTs Used in Pediatric MS?
MDedge Neurology
Can Online Patient Journals Improve MS Care?
MDedge Neurology
High dose of novel compound for relapsing-remitting MS shows promise
MDedge Neurology
MS medication withdrawn because of safety concerns
MDedge Neurology
Alemtuzumab-induced autoimmunity: getting closer to answers
MDedge Neurology
MS Medication Withdrawn Because of Safety Concerns
MDedge Neurology
The case for being open-minded about medical marijuana
MDedge Neurology
MRI finds PML in some natalizumab-treated patients despite negative CSF, no symptoms
MDedge Neurology